Intravascular versus surface cooling for targeted temperature management after out-of-hospital cardiac arrest: an analysis of the TTH48 trial.


Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
22 Feb 2019
Historique:
received: 19 11 2018
accepted: 25 01 2019
entrez: 24 2 2019
pubmed: 24 2 2019
medline: 1 10 2019
Statut: epublish

Résumé

The aim of this study was to explore the performance and outcomes for intravascular (IC) versus surface cooling devices (SFC) for targeted temperature management (TTM) after out-of-hospital cardiac arrest. A retrospective analysis of data from the Time-differentiated Therapeutic Hypothermia (TTH48) trial (NCT01689077), which compared whether TTM at 33 °C for 48 h results in better neurologic outcomes compared with standard 24-h duration. Devices were assessed for the speed of cooling and rewarming rates. Precision was assessed by measuring temperature variability (TV), i.e., the standard deviation (SD) of all temperature measurements in the cooling phase. Main outcomes were overall mortality and poor neurological outcome, including death, severe disability, or vegetative status. A total of 352 patients had available data and were included in the analysis; of those, 218 (62%) were managed with IC. A total of 114/218 (53%) patients with IC and 61/134 (43%) with SFC were cooled for 48 h (p = 0.22). Time to target temperature (≤ 34 °C) was significantly shorter for patients treated with endovascular devices (2.2 [1.1-4.0] vs. 4.2 [2.7-6.0] h, p < 0.001), but temperature was also lower on admission (35.0 [34.2-35.6] vs. 35.3 [34.5-35.8]°C; p = 0.02) and cooling rate was similar (0.4 [0.2-0.8] vs. 0.4 [0.2-0.6]°C/h; p = 0.14) when compared to SFC. Temperature variability was significantly lower in the endovascular device group when compared with SFC methods (0.6 [0.4-0.9] vs. 0.7 [0.5-1.0]°C; p = 0.007), as was rewarming rate (0.31 [0.22-0.44] vs. 0.37 [0.29-0.49]°C/hour; p = 0.02). There was no statistically significant difference in mortality (endovascular 65/218, 29% vs. others 43/134, 32%; p = 0.72) or poor neurological outcome (endovascular 69/218, 32% vs. others 51/134, 38%; p = 0.24) between type of devices. Endovascular cooling devices were more precise than SFC methods in patients cooled at 33 °C after out-of-hospital cardiac arrest. Main outcomes were similar with regard to the cooling methods.

Sections du résumé

BACKGROUND BACKGROUND
The aim of this study was to explore the performance and outcomes for intravascular (IC) versus surface cooling devices (SFC) for targeted temperature management (TTM) after out-of-hospital cardiac arrest.
METHODS METHODS
A retrospective analysis of data from the Time-differentiated Therapeutic Hypothermia (TTH48) trial (NCT01689077), which compared whether TTM at 33 °C for 48 h results in better neurologic outcomes compared with standard 24-h duration. Devices were assessed for the speed of cooling and rewarming rates. Precision was assessed by measuring temperature variability (TV), i.e., the standard deviation (SD) of all temperature measurements in the cooling phase. Main outcomes were overall mortality and poor neurological outcome, including death, severe disability, or vegetative status.
RESULTS RESULTS
A total of 352 patients had available data and were included in the analysis; of those, 218 (62%) were managed with IC. A total of 114/218 (53%) patients with IC and 61/134 (43%) with SFC were cooled for 48 h (p = 0.22). Time to target temperature (≤ 34 °C) was significantly shorter for patients treated with endovascular devices (2.2 [1.1-4.0] vs. 4.2 [2.7-6.0] h, p < 0.001), but temperature was also lower on admission (35.0 [34.2-35.6] vs. 35.3 [34.5-35.8]°C; p = 0.02) and cooling rate was similar (0.4 [0.2-0.8] vs. 0.4 [0.2-0.6]°C/h; p = 0.14) when compared to SFC. Temperature variability was significantly lower in the endovascular device group when compared with SFC methods (0.6 [0.4-0.9] vs. 0.7 [0.5-1.0]°C; p = 0.007), as was rewarming rate (0.31 [0.22-0.44] vs. 0.37 [0.29-0.49]°C/hour; p = 0.02). There was no statistically significant difference in mortality (endovascular 65/218, 29% vs. others 43/134, 32%; p = 0.72) or poor neurological outcome (endovascular 69/218, 32% vs. others 51/134, 38%; p = 0.24) between type of devices.
CONCLUSIONS CONCLUSIONS
Endovascular cooling devices were more precise than SFC methods in patients cooled at 33 °C after out-of-hospital cardiac arrest. Main outcomes were similar with regard to the cooling methods.

Identifiants

pubmed: 30795782
doi: 10.1186/s13054-019-2335-7
pii: 10.1186/s13054-019-2335-7
pmc: PMC6385423
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

61

Références

Crit Care Med. 2002 Nov;30(11):2481-8
pubmed: 12441758
Intensive Care Med. 2004 May;30(5):757-69
pubmed: 14767590
Resuscitation. 2004 Aug;62(2):143-50
pubmed: 15294399
Crit Care Med. 2006 Jul;34(7):1865-73
pubmed: 16715035
Resuscitation. 2007 Oct;75(1):76-81
pubmed: 17462808
Crit Care. 2007;11(4):R91
pubmed: 17718920
Neurocrit Care. 2007;7(2):109-18
pubmed: 17763832
Resuscitation. 2010 Jan;81(1):9-14
pubmed: 19854555
Neth Heart J. 2009 Oct;17(10):378-84
pubmed: 19949647
Resuscitation. 2010 Sep;81(9):1117-22
pubmed: 20599312
Resuscitation. 2010 Dec;81(12):1704-8
pubmed: 20926173
Crit Care Med. 2011 Mar;39(3):443-9
pubmed: 21169821
Resuscitation. 2012 Feb;83(2):151-8
pubmed: 22001003
Resuscitation. 2012 Aug;83(8):996-1000
pubmed: 22521448
Emerg Med J. 2013 Feb;30(2):91-100
pubmed: 22660549
Clin Res Cardiol. 2013 Aug;102(8):607-14
pubmed: 23644718
J Cardiol. 2014 Jan;63(1):46-52
pubmed: 23906526
N Engl J Med. 2013 Dec 5;369(23):2197-206
pubmed: 24237006
Crit Care. 2015 Mar 16;19:85
pubmed: 25880667
Circulation. 2015 Jul 21;132(3):152-7
pubmed: 26092672
Resuscitation. 2015 Nov;96:268-74
pubmed: 26386374
Circulation. 2015 Nov 3;132(18 Suppl 2):S465-82
pubmed: 26472996
Resuscitation. 2015 Oct;95:e71-120
pubmed: 26477429
JAMA. 2016 Oct 4;316(13):1375-1382
pubmed: 27701659
Crit Care. 2016 Nov 26;20(1):381
pubmed: 27887653
JAMA. 2017 Jul 25;318(4):341-350
pubmed: 28742911
Resuscitation. 2018 Mar;124:14-20
pubmed: 29288014
Crit Care. 2018 Mar 13;22(1):66
pubmed: 29534742

Auteurs

Chiara De Fazio (C)

Department of Intensive Care, Cliniques Universitaires de Bruxelles Hopital Erasme, Université Libre de Bruxelles (ULB), Route de Lennik, 808, 1070, Brussels, Belgium.

Markus B Skrifvars (MB)

Division of Intensive Care, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Department of Emergency Care and Services, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Eldar Søreide (E)

Critical Care and Anaesthesiology Research Group, Stavanger University Hospital, Stavanger, Norway.
Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Jacques Creteur (J)

Department of Intensive Care, Cliniques Universitaires de Bruxelles Hopital Erasme, Université Libre de Bruxelles (ULB), Route de Lennik, 808, 1070, Brussels, Belgium.

Anders M Grejs (AM)

Department of Intensive Care Medicine, Aarhus University Hospital, Aarhus, Denmark.

Jesper Kjærgaard (J)

Department of Cardiology B, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

Timo Laitio (T)

Division of Perioperative Services, Intensive Care Medicine and Pain Management, Turku University Hospital, Turku, Finland.

Jens Nee (J)

Medizinische Klinik mit Schwerpunkt, Nephrologie und Internistische Intensivmedizin, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Hans Kirkegaard (H)

Research Center for Emergency Medicine, Department of Emergency Medicine and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.

Fabio Silvio Taccone (FS)

Department of Intensive Care, Cliniques Universitaires de Bruxelles Hopital Erasme, Université Libre de Bruxelles (ULB), Route de Lennik, 808, 1070, Brussels, Belgium. ftaccone@ulb.ac.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH